These observations show that HLF and NFIL3 play important roles as transcriptional opposites in immune cell modulation and that their regulation may be critical to developing new or combination treatments for CTCL. This evidence concerns the gene NFIL3 and primary cutaneous T-cell non-Hodgkin lymphoma.